HI
LGND icon

HBK Investments’s Ligand Pharmaceuticals LGND Stock Holding History

HBK Investments’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-56,746
Closed -$1.66M – 1060
2014
Q3 		$1.66M Buy
56,746
+50,028
+745% +$1.66M 0.03% 426
2014
Q2 		$261K Buy
+6,718
New +$273K 0.01% 822

Other funds holding LGND

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBK Investments's LGND Position: Q4 2014 in Review

HBK Investments sold out of Ligand Pharmaceuticals (LGND) in Q4 2014, closing a stake of 56,746 shares — an estimated $1.66M sold.

HBK Investments first reported a position in LGND in Q2 2014 and held it in 2 quarters. The position peaked at $1.66M in Q3 2014. 180 funds tracked by Wall St. Rank hold LGND as of Q4 2014.

  • HBK Investments reported no remaining Ligand Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • HBK Investments sold 56,746 Ligand Pharmaceuticals shares in Q4 2014, an estimated $1.66M.
  • HBK Investments first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • HBK Investments's Ligand Pharmaceuticals position peaked at $1.66M in Q3 2014.
  • 180 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2014.

Based on HBK Investments's 13F filing for Q4 2014, filed 13 Feb 2015.